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Abstract
Several lines of evidence suggest that the normal form of the prion protein, PrP
C, exerts a neuroprotective activity against
cellular stress or toxicity. One of the clearest examples of such activity is the ability of wild-type PrP
C to suppress the
spontaneous neurodegenerative phenotype of transgenic mice expressing a deleted form of PrP (D32–134, called F35). To
define domains of PrP involved in its neuroprotective activity, we have analyzed the ability of several deletion mutants of
PrP (D23–31, D23–111, and D23–134) to rescue the phenotype of Tg(F35) mice. Surprisingly, all of these mutants displayed
greatly diminished rescue activity, although D23–31 PrP partially suppressed neuronal loss when expressed at very high
levels. Our results pinpoint the N-terminal, polybasic domain as a critical determinant of PrP
C neuroprotective activity, and
suggest that identification of molecules interacting with this region will provide important clues regarding the normal
function of the protein. Small molecule ligands targeting this region may also represent useful therapeutic agents for
treatment of prion diseases.
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Introduction
Prion diseases are invariably fatal neurodegenerative disorders
resultingfromtheconversionofthenormallya-helicalcellularprion
protein (PrP
C) into a misfolded b-sheet rich conformer called PrP
Sc.
While much research has focused on characterizing PrP
Sc as an
infectious agent, little progress has been made in defining the
normal function of PrP
C. Mice deleted for endogenous PrP are
relatively normal, with no gross anatomical or developmental
defects, providing few clues for understanding the physiological role
of this protein [1,2].
Several studies attempting to characterize PrP
C function demon-
strated that the protein may have a role in neuroprotection. For
example, overexpression of PrP
C has been shown to protect cells
against a variety of apoptotic stimuli, including Bax overexpression
[3,4], oxidative stress [5,6], and serum-deprivation [7,8]. However,
in almost all cases PrP
C expression provided only a modest
neuroprotective effect, making these cell assays difficult to reproduce
[9] and calling into question their physiological relevance.
Perhaps one of the most dramatic examples of PrP-dependent
neuroprotection has been observed in mice expressing mutant
forms of the protein. Transgenic expression of PrP molecules
deleted for residues 32–121, 32–134, 105–125 or 94–134 leads to
a spontaneous neurodegenerative phenotype [10,11,12], as does
ectopic expression of Doppel, a PrP paralog structurally
homologous to the C-terminal half of PrP [13,14,15,16].
Intriguingly, co-expression of wild type (WT) PrP counteracts
the neurodegenerative effect of each of these PrP mutants and
Doppel, providing a way to test PrP neuroprotective activity in vivo.
For example, PrP molecules deleted for most (D32–80) or all (D32–
93) of the octapeptide repeats rescued mice expressing D32–134
PrP [referred to as Tg(F35)] as efficiently as WT PrP, indicating
that this region is not essential for neuroprotection [10,17].
Conversely, PrP carrying a deletion of 23–88 had an impaired
ability to rescue from Doppel, despite being expressed at higher
levels than WT PrP [18]. Collectively, these results suggest that the
N-terminus of PrP, particularly residues 23–31, is critical for PrP
rescuing activity. These residues (
23KKRPKPGGW
31) are highly
conserved across mammalian species and have several known
functions, including regulating PrP endocytosis [19,20,21], binding
to glycosaminoglyans (GAGs) [22,23,24] and the ability to act as a
protein transduction domain [25].
In order to directly address the role of residues 23–31 in the
neuroprotective activity of PrP, we have compared the ability of
several specific N-terminal deletion mutants, including D23–31,
D23–111, or D23–134 PrP, to reverse F35-induced toxicity in Tg
mice. We found that each of these molecules showed greatly
impaired rescuing activity, despite considerably higher expression
levels compared to WT PrP. These results demonstrate that
residues 23–31 are crucial for the neuroprotective function of PrP.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
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Use Committee (Permit Number: AN-14997).
Construction of transgenic mice
Bridge PCR amplification was used to generate D23–31 PrP
(containing a 3F4 epitope tag) using in the yeast p426GPD vector [26].
D23–31 PrP was subcloned into the mammalian pCNDA3.1 (+)H y g r o
vector (Invitrogen, Carlsbad, CA) under the control of the CMV
promoter. To create a non 3F4-tagged version of this plasmid, the C-
terminal (3F4-containing) fragment of the plasmid described above was
released by digestion with restriction enzymes AgeI and XbaI and the
corresponding portion of the untagged cDNA was ligated to the D23–
31 vector. Using this non-3F4-tagged D23–31 construct, the following
primers were used to PCR-amplify PrP: FWD (59 – TATATACTC
GAGGCCGCCACCATGGCGAACCTTGGCTACTGG – 39)a n d
REV (59 – CTCGAGCTT GTCATCGTCGTCCTTGTAGTCT-
CATTATCCCACGATCAGGAAGATGAG – 39).
Ac D N Ae n c o d i n gm u r i n eC 1( D23–111) was generated by PCR
amplification. The following primers were used: FWD (59 – TCCGA
AAGCTTCTCGAGGCCGCCACCA TGGCGAACCTTGGC-
TACTGGCTGCTGGCCCTCTTTGTGACTATGTGGACTG-
ATGTCGGCCTCTGCAGGCCCATGATCCATTTTGGC – 39)
and REV (59– CGGACTCTAGACT CGAGTCATCATCCCAC-
GATCAGGAAGAT – 39). The resulting PCR product was digested
with HindIII and XbaI and cloned into pcDNA 3.1 (+)H y g r o .
To create both Tg (D23–31) and Tg (D23–111) mice, the
corresponding sequences were released from the pcDNA3.1 (+)
Hygro plasmid by digestion with XhoI and ligated into the Xho I
site of MoPrP.Xho [27] under the control of the mouse half-
genomic PrP promoter. The resulting colonies were checked for
the presence of the insert using PCR primers P1 and P4 [28], and
then sequenced to confirm the correct sequence and orientation.
The transgene was released from the recombinant plasmid by
NotI digestion, purified with a GFX column (GE), and injected
into the pronuclei of fertilized eggs from C57BL6/J6CBA hybrid
mice. Tg (D23–31) founders were bred to Prn-p
2/2 mice on the
C56BL6/J background (EMMA), and Tg(D23–111) founders were
bred initially to Tga20
+/+ mice on a C57BL6/CBA/129
background (EMMA), and were then back-crossed to Prn-p
2/2
mice on the C56BL6/J background.
Generation of Tg(D23–134) mice has been described elsewhere
[29]. Mice expressing D23–31, D23–111, or D23–134 on the Prn-
p
2/2 background were mated to F35
+/0 Prn-p
+/2 mice to generate
the genotypes used in this study. All transgenes were hemizygous.
Genotyping of transgenic mice
Mice were genotyped by PCR analysis of tail DNA prepared
using the Puregene DNA Isolation Kit (Gentra Systems, Minneap-
olis, MN). The Prn-p allele was detected with primers E2 (referred to
as P2 in [28]) and E4 [12]. Primers E2 and K4 (59 – GTGAG
ATGACAGGAGATCCTGCC – 39) recognized the PrP knockout
allele. Primer pair 890 (59 – CTCGAGGCCGCCACCATG – 39)
and P4 [28] recognized D23–31, D23–111, and D23–134 PrP
transgenes, and primers 913 (59 – AAGCGGCCAAAGCCTG-
GAGGGTGG – 39) and P4 recognized the F35 transgene.
Statistical Analysis
Animals were sacrificed when terminally ill. The age of each
mouse at the time of sacrifice was used to compare the lifespans of
mice of the indicated genotypes using the Kruskal-Wallis test with
Dunn’s secondary testing. All statistical analyses were performed
using the GraphPad Prism 5 program.
Immunofluorescence and PIPLC treatment
BHK cells grown in PDL-coated 8 well chamber slides (BD
Biosciences) were transiently transfected w/0.25 mg DNA and
0.75 mg Lipofetamine2000 (Invitrogen) per well. At 24 hours
post-transfection, cells were washed with PBS, fixed in 4%
paraformaldehyde for 10 minutes, permeabilized with 0.2%
Triton X-100, and blocked in 2% goat serum in PBS. Cells were
then stained with the following antibodies in blocking solution:
6D11 (R. Kascsak), 6H4 (Prionics), and Giantin (Covance),
followed by incubation with fluorescently conjugated secondary
antibodies (Molecular Probes), staining with DAPI, and visualiza-
tion with a fluorescence microscope. For surface staining and
PIPLC treatment, the same transfection protocol was followed
except that plasmids encoding PrP and dsRedER were co-
transfected (0.25 mg DNA each). At 24 hours post-transfection,
cells were incubated in the absence or presence of PIPLC (Sigma)
at 0.5 U/ml for 2 hours prior to surface staining with anti-PrP
antibody 6D11 or 6H4, followed by incubation with a fluores-
cently conjugated secondary antibody (Molecular Probes) and
staining with DAPI.
Cerebellar graunule cell cultures
Cultures were performed as described previously [12]. After 4–5
days in culture, cells were fixed with 4% paraformaldehyde,
surface stained with anti-PrP antibody 6H4, and then incubated
with AlexaFlour 488-coupled goat anti-mouse IgG.
Histology
Mouse brains were fixed in 4% paraformaldehyde before
embedding in paraffin and cutting 4 mm sections. Paraffin sections
were stained with hematoxylin and eosin as described previously
[28], and were imaged with a Nikon TE-2000E inverted
microscope.
PNGaseF treatment and Western Blotting
Brain homogenates (10% w/v) were made by mechanically
dissociating frozen brains in PBS using plastic pestles (South Jersey
Precision Tool and Mold Inc., Vineland, NJ). Homogenates were
then lysed in 0.5% NP-40/0.5% DOC, pH 7, and total protein
levels were quantified with the BCA kit (Pierce, Rockford, IL). To
de-glycosylate PrP, a 20 mg aliquot of total protein was treated
with PNGase-F (N-glycosidase-F, New England Biolabs, Beverly,
MA) according to the manufacturer’s instructions. Samples were
subjected to Western blotting and probed with anti-PrP antibody
6H4 (Prionics) followed by goat anti-mouse IgG (Pierce, Rockford,
IL). Blots were developed with Millipore immobilon Western
Chemiluminescent HRP substrate prior to imaging on a Biorad
Chemidoc XRS system.
Immunoprecipitation
Brain homogenates (10% w/v in PBS) were lysed in 0.5%
CHAPS/0.5% NP-40 containing protease inhibitors (complete
Mini EDTA-free, Roche), subjected to low-speed centrifugation to
remove DNA and cellular debris, and total protein was
quantitated using the BCA kit. Prior to immunoprecipitation,
30 mg of 6D11 antibody was coupled to 500 ml of anti-IgG
Dynabeads (Dynal, Carlsbad, CA) in presence of 20 mM dimethyl
pimelimidate dihydrochloride (Sigma), followed by washing and
resuspending in PBS containing 0.1% BSA. Lysates were diluted
to 0.5 mg/ml, pre-cleared with naked beads, and PrP was
immunoprecipitated overnight with 50 ml of antibody-coupled
Dynabeads, or with naked beads, washed, and collected with a
magnet. Beads were re-suspended in 0.5% NP-40/0.5% DOC,
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digestion, samples were boiled in SDS-loading sample buffer prior
to Western blotting.
Results
N-terminal PrP deletion mutants have a cellular
localization pattern similar to WT PrP
Before examining the ability of N-terminal deletion mutants to
rescue the toxicity of F35 PrP in vivo, we characterized the
localization of these proteins in cultured cells. To demonstrate that
D23–31, D23–111, and D23–134 are correctly delivered to the
plasma membrane, BHK cells expressing either WT or mutant PrP
were incubated with or without phosphatidylinositol-specific phos-
pholipase C (PIPLC) then surface-stained with an anti-PrP antibody.
We found that, like WT PrP, D23–31, D23–111, D23–134, and F35
PrPswerereleased byPIPLC treatment,demonstrating that theyare
all attached to the outer leaflet of the plasma membrane via a
phospholipase-cleavable GPI anchor (Figure 1 A–L). Additionally,
WT PrP and each of the N-terminal mutants co-localized with the
Golgi marker, giantin, in permeabilized BHK cells, indicating that
the proteins traffic through the Golgi on their way to the plasma
membrane (Figure 1 M–R).
To confirm that deletion of the N-terminal residues does not
alter PrP localization in neurons, we also examined the
localization of D23–31 and D23–134 PrP in cerebellar granule
neurons cultured from the respective transgenic mice. Immuno-
fluorescent staining of cell surface PrP showed that, like WT PrP,
D23–31 and D23–134 PrPs are expressed on the plasma
membrane of cell bodies as well as neurites (Figure 2).
Deletions of the N-terminus of PrP compromise its
rescuing ability
In order to define the role of the N-terminal region of PrP in
neuroprotection, we compared the lifespan of mice co-expressing
F35 PrP along with either WT PrP or three different, N-terminally
deleted mutants (D23–31, D23–111, or D23–134). All transgenes
were expressed under the control of the PrP half-genomic
promoter on a Prn-p
2/2 background. D23–111 PrP corresponds
to the major, physiologically occurring, C-terminal fragment of
PrP, called C1. In this study, we utilized two lines of Tg(D23–31)
mice with expression levels of 16 and 66 with respect to
endogenous PrP, one line of Tg(D23–111) mice with an expression
level of 76, and one line of Tg(D23–134) mice with an expression
level of 16(Figure 3A, compare lanes 3–6 to lane 1). The Tg(F35)
Figure 1. D23–31, D23–111, D23–134, and D32–134 (F35) PrP are GPI-anchored and have a cellular localization pattern similar to WT
PrP. (A–L) The indicated constructs were transiently expressed in BHK cells along with dsRedER. Cells were incubated in the absence (A–F) or
presence (G–L) of PIPLC, then surface stained for PrP (A–C, G–I: 6D11 or D–F, J–L: 6H4) on ice prior to incubating with secondary antibody (dsRedER
signal in red, PrP in green). DAPI staining is shown in blue for panels D–F, J–L. Like WT PrP (H), the mutant PrP molecules are released from the plasma
membrane by PIPLC treatment (I–L). (M–R) BHK cells transfected with the indicated constructs were permeabilized and stained with anti-PrP
antibody [M–O: 6D11, P–R: 6H4 (green)], anti-giantin antibody (red), and DAPI (blue). Like WT PrP, each mutant is present both at the cell surface and
intracellularly, where it colocalizes with the Golgi marker, giantin. [Scale bar in A (applicable to panels A–L, P–R)=25 mm. Scale bar in M–O=15 mm.].
doi:10.1371/journal.pone.0025675.g001
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shown in Figure 3, each mutant migrated at the expected
molecular weight and was glycosylated, with the di-glycosylated
band appearing as the predominant form.
Tg(F35)/Prn-p
+/2 mice were crossed with Tg(D23–31
16),
Tg(D23–31
66), Tg(D23–111
76), or Tg(D23–134
16), all on a Prn-
p
2/2 background, to retrieve the doubly transgenic genotypes
shown in Table 1. To assess relative expression levels of the
Figure 2. Cell surface staining of PrP in cerebellar neurons from non-Tg, Tg(D23–31
16), and Tg(D23–134) mice. Cerebellar granular
neurons cultured from mice of the indicated genotype were stained for cell surface PrP (6H4, green). Like WT PrP from non-Tg mice, both D23–31 and
D23–134 PrPs are present on the cell surface and along neurites.
doi:10.1371/journal.pone.0025675.g002
Figure 3. Expression of transgenes. (A) Brain lysates from a non-transgenic WT mouse (expressing 16PrP), and from Tg mice expressing F35 PrP
(26), D23–31 PrP (16and 66), D23–111 PrP (76), and D23–134 PrP (16) were Western blotted and probed with anti-PrP antibody 6H4. (B) Lysates
from the brains of 10 week old mice were treated with PNGase F to removed N-linked oligosaccharides. Digestion products were subjected to
Western blotting using antibody 6H4 to detect PrP. Single and double asterisks mark the positions of the endogenous C1 and C2 cleavage fragments,
respectively.
doi:10.1371/journal.pone.0025675.g003
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mice at 10 weeks of age with PNGase F to removed N-linked
oligosaccharides, followed by Western blotting (Figure 3B). These
results demonstrated that levels of D23–31, D23–111, or D23–134
PrPs were not affected by co-expression of the F35 mutant, and
conversely that the level of F35 PrP was not affected by co-
expression of the other mutants (Figure 3B, lanes 6–10).
Mice expressing D23–31, D23–111, or D23–134 PrP in the
absence of F35 PrP showed no evidence of spontaneous disease
and had normal lifespans (not shown).
As reported previously [10], co-expression of 0.56 WT PrP
completely suppressed neurological signs of disease and extended the
lifespan of F35 mice to more than 1 year (Table 1; Figure 4, black
line). In contrast, co-expression of each of the three N-terminal
Table 1. N-terminally deleted forms of PrP are impaired in their ability to suppress the neurodegenerative phenotype of Tg(F35)
mice.
Genotype Expression level of rescue molecule Age at death (days)
Tg(F35)/Prn-p
2/2 0 88.168.1 (n=30)
Tg(F35)/Prn-p
+/2 0.56 .365 (n=12) **
Tg(F35/D23–31)/Prn-p
2/2 16 100.9614.1 (n=12)
Tg(F35/D23–31)/Prn-p
2/2 66 159.1622.2 (n=10) **
Tg(F35/D23–111)/Prn-p
2/2 76 97.8610.2 (n=10)
Tg(F35/D23–134)/Prn-p
2/2 16 126.4614.2 (n=8) *
The genotype, number of mice, age at death, and relative expression levels PrP are shown for each transgenic line. While 0.56expression of WT PrP greatly prolongs the
lifespan of Tg(F35) mice, the N-terminal mutants have only a modest effect on lifespan, even at elevated expression levels. Asterisks indicate statistically significant
differences in age at death compared to Tg(F35)/Prn-p
2/2 mice (** p,0.001, * p,0.01 by Kruskal-Wallis with Dunn’s secondary test).
doi:10.1371/journal.pone.0025675.t001
Figure 4. Survival of mice co-expressing N-terminal deletion mutants. Each point represents the percentage of animals alive at the indicated
age. Statistical analyses are shown in Table 1.
doi:10.1371/journal.pone.0025675.g004
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failed to reverse the F35 clinical phenotype, with all mice displaying
progressive tremor, ataxia, and hind limb paresis and eventually
dying from neurological illness. Moreover, each of the mutant PrP
molecules had a much weaker effect than WT PrP on extending the
lifespan of the mice. For example, although 66expression of D23–31
PrP produced a statistically significant lengthening of lifespan, 16
expression had no significant effect on survival (Table 1; Figure 4,
blue and purple lines, respectively). The D23–111 mutant, which
carries a larger deletion, provided no statistically significant rescue
even when expressed at 76 (Table 1; Figure 4, green line).
Surprisingly, D23–134 PrP showed a more substantial rescue than
the other two mutants, despite the fact that it harbors the longest
deletion and was expressed at only 16 (Table 1; Figure 4, orange
line).
Collectively, these results indicate that each of the N-terminal
deletion mutants is impaired compared to WT PrP in its ability to
suppress neurological symptoms and death in Tg(F35) mice, even
when expressed at supraphysiological levels. Moreover, deletion of
the 9 amino acid, polybasic domain (residues 23–31) is sufficient to
dramatically compromise rescuing activity.
N-terminal deletion mutants do not reverse Tg(F35)
pathology
The pathological hallmarks of neurodegeneration in Tg(F35)
mice include prominent loss of cerebellar granular neurons
(CGNs) and vacuolation of white matter in the cerebellum and
other brain areas. In order to determine if the N-terminal deletion
mutants were able to rescue these pathological signs, we analyzed
brain sections taken from mice co-expressing F35 and either WT,
D23–31, D23–111, or D23–134 PrP. Mouse brains were analyzed
at 3 weeks (pre-symptomatic), 10 weeks (symptomatic), and time of
terminal disease (depending on the different genotypes), and
sections were stained with hematoxylin/eosin.
At 3 weeks, the cerebellum of Tg(F35) mice on a PrP-null
background appears slightly shrunken (Figure 5A), although the
granule cell layer (Figure 5G) and the white matter (Figure 5M) are
still intact. At both 10 weeks and at the time of terminal disease, the
cerebellum of these mice is severely atrophic (Figure 6A and 7A),
with evident loss of CGNs (Figure 6G and 7G) and white matter
vacuolation (Figure 6M and 7M). As expected, no pathological signs
weredetected atanytime point inF35 miceco-expressing 0.56WT
PrP (Figure 5–7, panels F, L and R).
The cerebellum of Tg(F35) mice co-expressing each of the three
N-terminal deletion mutants appeared normal at 3 weeks of age
(Figure 5 B–E, H–K, N–Q). However, by 10 weeks of age there
was noticeable cerebellar atrophy (Figure 6 B, D, E), dramatic loss
of CGNs (Figure 6 H, J, K) and accumulation of vacuoles in the
cerebellar white matter (Figure 6, N, P, Q) of Tg(F35) mice co-
expressing D23–31 (16), D23–111 (76), or D23–134 (16) PrP.
These neuropathological changes were even more marked at the
time of terminal illness (Figure 7). Unexpectedly, co-expression of
D23–31 PrP at high levels (66) prevented the loss of CGNs at both
10 weeks (Figure 6I) and at the time of terminal disease (Figure 7I),
although these mice still showed prominent white matter
vacuolation at both time points (Figure 6 and 7, O).
These results demonstrate that the N-terminal region of PrP is
necessary to fully rescue the pathological changes induced by
Figure 5. F35 mice co-expressing N-terminal deletion mutants are normal at 3 weeks. Animals of the indicated genotypes were sacrificed
at 3 weeks and brain sections were stained with hematoxylin and eosin. Images show the whole cerebellum (A–F), the granule cell layer of the second
cerebellar lobe (G–L), and the cerebellar white matter (M–R). Scale bars=1 mm (A–F) and 100 mm (G–R).
doi:10.1371/journal.pone.0025675.g005
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31
66) mice display prominent white matter vacuolation without
substantial granule cell loss suggests that white matter pathology
itself is sufficient for causing death in F35 mice.
F35 does not co-immunoprecipitate with WT or D23–31
PrP
One possible explanation for the rescuing ability of WT PrP in
Tg(F35) mice is that the normal protein physically interacts with
the F35 mutant, preventing its toxic effect. Our results suggest that
such interaction would involve residues 23–31. Consequently,
deletion of these residues should decrease or abolish binding of
WT PrP to F35 PrP.
To test the possibility that WT but not D23–31 PrP directly
interacts with the F35 mutant, we performed co-immunoprecip-
itation experiments on brain homogenates. Beads coated with
antibody 6D11, which recognizes an epitope (residues 95–100)
deleted in F35, were used to pull-down PrP molecules from F35
mice co-expressing either WT or D23–31. After immunoprecip-
itation, proteins were enzymatically de-glycosylated to discrimi-
nate between WT, D23–31 and F35 PrPs based on their migration
on SDS-PAGE. Antibody 6H4, which recognizes a C-terminal
epitope (144–152), was then used to detect all PrP species by
Western blotting. As expected, the F35 protein was not
immunoprecipitated by naked beads (Figure 8, lane 3), or by
6D11 (Figure 8, lane 2), although the protein was still detected in
the input lane (Figure 8, lane 1). Conversely, both WT (Figure 8,
lane 4) and D23–31 PrP (Figure 8, lane 6) were efficiently
immunoprecipitated by 6D11, but not by naked beads (Figure 8,
lanes 5 and 7). However, F35 PrP did not co-immunoprecipitate
with either WT or D23–31 PrP (Figure 8, lanes 4, 6) suggesting
that the rescuing activity of WT PrP does not rely on a direct
interaction with the toxic mutant.
Discussion
Expression of WT PrP is known to suppress the spontaneous
neurodegenerative phenotype induced by several N-terminal
deletion mutants of PrP. For example, Tg(F35) mice expressing
D32–134 PrP on a Prn-p
2/2 background become terminally ill
within three months after birth, while co-expression of 0.56
endogenous, WT PrP prolongs the lifespan of these animals to more
thanoneyear[10].Inthepresentstudy,wehavedefinedtheregions
ofPrPparticipatinginthisneuroprotectiveactivity,andshowedthat
deletions encompassing the N-terminal polybasic domain (residues
23–31) significantly impair the ability of PrP to reverse neurode-
generative phenotype of Tg(F35) mice. We found that, although
D23–31 PrP displayed greatly diminished rescuing activity, over-
expression of the protein was able to prevent CGN loss, although
white matter vacuolation and clinical symptoms still ensued,
demonstratingthe independent roles ofthese twokinds of pathology
in the death of the animals. We failed to observe co-immunopre-
cipitation of WT and F35 PrP, suggesting that the rescuing ability of
the WT protein does not depend on a physical interaction with the
mutant protein. Therefore, deletion of residues 23–31 could
compromise PrP neuroprotective activity by disrupting its associ-
ation with other membrane-bound molecules.
Figure 6. D23–31, D23–111, and D23–134 PrP are impaired in their ability to suppress Tg(F35) neuropathology at 10 weeks. Animals
of the indicated genotypes were sacrificed at 10 weeks. Histological staining, order of images, and scale bars are identical to Figure 5. Mice
expressing F35 in the presence or absence of D23–31
16, D23–111
76,o rD23–134
16 PrP display marked loss of CGNs (G, H, J and K), as well as
vacuolation of the cerebellar white matter (M, N, P and Q). Conversely, expression of D23–31
66PrP prevents loss of CGNs (I), but not white matter
vacuolation (O).
doi:10.1371/journal.pone.0025675.g006
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activity of PrP
The main conclusion of our study is that N-terminal deletion
mutants are significantly impaired in their ability to reverse the
phenotype of Tg(F35) mice. This conclusion holds true for three
successive deletions including D23–31, D23–111, and D23–134.
The most substantial rescue was seen by over-expressing D23–31
PrP by six-fold, although even at this expression level the protein
did not prevent neurological symptoms or death of Tg(F35) mice.
In comparison, an expression level of WT PrP that is 12 times
lower (0.56) is sufficient for fully reversing the Tg(F35) phenotype
and allowing the animals to have a normal lifespan. Surprisingly,
D23–134 PrP, which harbors the longest deletion, showed a mild
rescuing effect at physiological expression levels (16). It is
currently unclear why this molecule would display a better
rescuing ability than either D23–31 or D23–111 PrP, when
expressed at 16 and 76 respectively. Possibly, the presence of
residues between 31 and 134 negatively impacts whatever
interactions are important for the rescuing activity of PrP.
While this is the first study to examine the role of the N-
terminal, polybasic domain in suppressing the phenotype of
Tg(F35) mice, previous studies have investigated whether the N-
terminal domain of PrP can exert a neuroprotective activity. A
peptide corresponding to PrP residues 23–50 has been shown to
reduce the formation of reactive oxygen species in response to
serum deprivation in cultured cells [30]. Other studies have
analyzed the ability of two N-terminally deleted PrPs (D23–88 and
D25–50) to reverse neurodegeneration in mice ectopically
expressing Doppel [18,31]. Since it lacks the flexible N-terminus,
Figure 7. N-terminal deletion mutants do not suppress Tg(F35) neuropathology at time of terminal disease. Histological staining, order
of images, and scale bars are identical to Figure 5, except that animals were sacrificed when terminally ill. As for 10 week old animals, D23–31
66PrP
expression rescues loss of CGNs (I), but not white matter vacuolation (O), while co-expression of D23–31
16, D23–111
76,o rD23–134
16PrP does not
prevent either CGN loss (G, H, J and K) or white matter vacuolation (M, N, P and Q).
doi:10.1371/journal.pone.0025675.g007
Figure 8. F35 does not interact with either WT PrP or D23–31
PrP in co-immunoprecipitation experiments. Brain lysates from
mice expressing F35 PrP in the presence or absence of either WT or
D23–31 PrP were immunoprecipitated with Dynabeads coupled to anti-
PrP antibody 6D11, or with naked beads as a control. Immunoprecip-
tated proteins were then analyzed by Western blotting with anti-PrP
antibody 6H4. The arrowhead indicates the position of F35 PrP. The
faint band appearing in lane 6 between 15 and 20 kDa is distinguish-
able from the F35 protein, and could represent a C-terminal fragment of
D23–31 PrP.
doi:10.1371/journal.pone.0025675.g008
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these proteins may induce toxicity via a similar mechanism.
Interestingly, while D23–88 PrP completely lacked a neuropro-
tective ability, the expression of D25–50 PrP led to a rescue of
Doppel-induced neurodegeneration [18,31], suggesting that resi-
dues 23 and 24 by themselves, but not the octapeptide repeats,
may impart some protective activity. These data, taken together
with those in our study, suggest that the extreme N-terminus of
PrP represents a primary determinant of its neuroprotective
activity in both Doppel and Tg(F35) mice.
In addition to playing a role in neuroprotection, residues 23–31
also appear to be important in several neurotoxic activities of PrP.For
example, mice expressing D23–134 PrP, which is equivalent to the
F35 mutant missing residues 23–31, showed no evidence of
neurodegeneration [29]. Additionally, either deleting or mutating
residues 23–31 in the context of D105–125 PrP completely abrogates
the ion channel activating and aminoglycoside-sensitizing activities of
this protein in cells [29,32]. Collectively, these results demonstrate a
critical role for the N-terminal, polybasic domain in regulating both
the neurotoxic and neuroprotective functions of PrP.
White matter pathology and neuronal loss in F35 mice
are mechanistically distinct
We have observed that terminally ill Tg(F35) mice over-
expressing D23–31 PrP by six-fold displayed extensive white
matter pathology with little granule cell loss. The details of this
white matter pathology have not been dissected, and may be
related to either axon or myelin dysfunction. However, the general
theme of white matter pathology in the absence of CGN loss is
paralleled by several other transgenic models, including Tg(D94–
134) [11] and Tg(D105–125/Tga20) [12]. Moreover, it has been
reported that oligodendrocyte-specific expression of WT PrP
reversed white matter pathology and dramatically improved
survival in Tg(F35) and Tg(Dpl) mice without preventing neuronal
loss [33]. Collectively, these results suggest that white matter
abnormalities and neuronal loss are mechanistically distinct, and
that the former pathology may be the immediate cause of clinical
symptoms and death in several kinds of Tg mice expressing toxic
PrP mutants or Doppel. Interestingly, recent work has shown that
PrP may play a role in myelin maintenance [34], raising the
possibility that this functional role may be subverted by certain
mutations in the PrP molecule.
The naturally occurring, C1 proteolytic fragment of PrP is
not neuroprotective
The PrP molecule expressed by Tg(D23–111) mice is equivalent
to a physiologically occurring, C-terminal cleavage fragment of PrP
termed C1. C1 is produced by cleavage between residues 111 and
112 by the ADAM10 and ADAM17 proteases [35]. This cleavage
leaves the C-terminal half of PrP, composed of residues 112–230,
anchored to the plasma membrane, and releases an N-terminal
fragment called N1. Previous work has shown that Prn-p
2/2 mice
display a chronic demyelinating polyneuropathy, and that this
pathology is rescued by co-expression of transgenes that result in
production of C1 but not by transgenes encoding PrP forms non-
permissive for cleavage [34]. These authors concluded that
regulated proteolysis of PrP
C is essential for myelin maintenance.
In contrast, our data suggest that C1 (D23–111) is incapable of
preventing the neuropathological changes, including white matter
pathology,induced byF35PrP. Whileitispossiblethat Tg(F35) and
Prn-p
2/2 mice suffer from different types of white matter
dysfunction, an alternative hypothesis is that N1, rather than C1,
is necessary for the rescue effect in both kinds of mice. The lines
examined by Bremer et al. that are non-permissive for cleavage
would generate neither N1 nor C1, while our Tg(D23–111) lines
produce only a C1-like fragment. This explanation is supported by
previous experiments showing that N1 has a neuroprotective
function in retinal cells via modulation of the p53 pathway both in
vitro and in vivo [36]. Although more work remains to elucidate the
significanceoftheN1/C1cleavage inthebrain,we haveshown that
the C1 protein is incapable of providing a neuroprotective effect in
the context of F35-induced neurodegeneration.
How do residues 23–31 play a role in the neuroprotective
activity of PrP?
One explanation is that these residues form part of a binding
site between PrP and an interacting molecule on the cell surface.
In this study, we provided evidence that WT and F35 PrP do not
physically interact, although it remains possible that these two
proteins engage in a weak or transient interaction that is not
detectable in the co-immunoprecipitation experiment we per-
formed. Previous work suggested that PrP is cabable of forming a
dimer [37,38,39], but the results of our co-immunoprecipitation
experiment indicate that such dimerization may not occur
between heterologous molecules of PrP, such as F35 and WT, at
least under the conditions we have used.
Our results raise the possibility that WT rescuing activity relieson
interaction with an alternative binding partner whose binding to
PrPisdependentonthepresence ofresidues23–31.Previousstudies
have identified molecules (including proteins, glycans, and lipids)
that interact with PrP, some of which have been found to bind
specifically to the N-terminus of PrP. These include the low-density
lipoprotein receptor-related protein 1 (LRP1), which modulates the
endocytosis of PrP [40]. Disruption of this region prevents this
endocytosis of PrP [19,20,21,41], and influences its half-life and rate
of trafficking to the plasma membrane [41]. These residues are also
a binding site for GAGs [22,23,24], which can mediate binding
between PrP and the 37 kDa/67 kDa laminin receptor [42].
Additionally, the polybasic region is capable of interacting with the
plasma membrane as a protein transduction domain [25] or an
antimicrobial peptide [43], although several studies indicate that its
ability to insert into the membrane also requires the presence of the
octapeptide repeat region [44,45]. In PrP that is targeted to the
cytoplasm due to abnormal folding or processing, these residues can
function as a nuclear localization signal [46] and interact with
tubulin [47], although these interactions may not be physiologically
relevant in the presence of normally processed PrP, which is
localized primarily to the outer leaflet of the plasma membrane.
Whether these or other, undefined interactions are relevant to the
neuroprotective function of PrP remains unresolved.
Of note, a recent report identifies residues 23–27 of PrP as one
of the two sites that bind oligomers of the Alzheimer’s Ab peptide
[48], suggesting a role for this region in mediating the synaptotoxic
effects of these oligomers. Given the role of the N-terminal
polybasic domain in determining the neuroprotective properties of
PrP, as well as its binding to other toxic oligomers [49], this region
may prove to be an important therapeutic target in prion as well as
other neurodegenerative disorders.
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